On the Radar…

InDevR, Inc and the University of Colorado Technology Transfer office announced today that InDevR has licensed FluChip technology from the University. InDevR CEO Kathleen Rowlen, also a Professor at CU, was a lead investigator in the research behind FluChip in a combined effort between CU and the CDC in research sponsored by the NIH. InDevR plans to test several versions of the FluChip in development to see if it can locate the swine flu in the current outbreak from human H1N1 strains. The M version of the chip has demonstrated the ability to distinguish human-adapted viruses from non-human strains in previous testing. Traditional flu testing including currently available rapid immunoassays are not able to make the distinction necessary for local health departments to confirm diagnosis. InDevR will seek to create a test to identify swine flu that is easy enough for any lab with PCR capabilities to use through combining the FluChip assay with an innovative detection technology (Non Enzymatic Signal Amplification or NESA) it previously licensed from CU. Boulder-based InDevR is a privately-held biotechnology company focused on the development of virus-related diagnostics.